Bayer chooses Metra bone resorbtion assay:
This article was originally published in Clinica
Executive Summary
Bayer will market Metra Biosystems' Pyrilinks-D deoxypyridinoline (Dpd) bone resorbtion test worldwide, with the exception of Japan, as an automated assay on its Immuno 1 system. The test is already offered by Chiron Diagnostics and Diagnostic Products on their automated platforms. The test measures Dpd, the accepted bone resorbtion marker, which is excreted in the urine in an unmetabolised form and is the only recognised test on the market, according to the company.